The Skin Allergy Risk Assessment-Integrated Chemical Environment (SARA-ICE) Model for UN GHS Classification – An Evaluation and Application in Case Studies

G. Reynolds[1], J. Reynolds[1], N. Gilmour[1], J. Strickland[2], E.N. Reinke [2], D. Germolec[3], J. Truax[2], D.G. Allen[2], G. Maxwell[1], N. Kleinstreuer[3]

[1]SEAC Unilever, MK44 1LQ, United Kingdom; [2]Inotiv, Research Triangle Park, NC; [3]NIH/NIEHS/DTT/NICEATM, Research Triangle Park, NC

Abstract Number: 4454
Poster Number: P327

Introduction

In chemico and in vitro OECD test guideline methods are available for use in skin sensitisation assessment. No single method can currently be used to determine skin sensitisation but can be used as part of a defined approach (DA). DAs allow new approach methods (NAMs) to be used in combination via a fixed data interpretation procedure. Currently the DAs accepted for regulatory use only provide information for skin sensitisation hazard and potency classification and are not suitable for point of departure (PoD) determination for use in quantitative risk assessment.

A collaboration between Unilever and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) has developed the Skin Allergy Risk Assessment-Integrated Chemical Environment (SARA-ICE) Model, a DA developed upon principles of the Unilever SARA Model (Reynolds et al. 2019, Reynolds et al. 2022). The SARA-ICE Model is designed to provide a weight-of-evidence (WoE) PoD and United Nations Globally Harmonized System for Classification and Labelling of Chemicals (GHS) classification prediction for use in skin sensitisation assessments.

The SARA-ICE core dataset utilises data within the publicly available Integrated Chemical Environment (ICE) database in addition to the published Unilever SARA database and Cosmetics Europe database. The model is constructed within the Bayesian statistical framework and allows for determination of a human relevant PoD, defined as the dose with a 1% chance of inducing sensitisation following a human predictive patch test (HPPT) exposure. The PoD can be inferred using any combination of HPPT (human repeat insult patch test or human maximisation test), in vivo local lymph node assay (LLNA), and NAM (in chemico direct peptide reactivity assay [DPRA] and kinetic DPRA and in vitro KeratinoSens™, h-CLAT, or U-SENS™) data. For a chemical of interest, the model returns the probability of each GHS classification conditional on the distribution of the ED01.

Here we show some initial outputs of the SARA-ICE Model evaluation and its application for GHS classification of methylisothiazolinone (MIT) as a case study. Isothiazolinones are widely used as antimicrobial preservatives in cosmetics and are known to have skin sensitising potential. This SARA-ICE analysis builds upon the work conducted by Strickland et al. 2022, where Shiseido Artificial Neural Networks (ANN) non-animal DAs for skin sensitisation were evaluated for PoD estimates for use in quantitative risk assessment for isothiazolinones.

SARA-ICE Training Dataset

The SARA-ICE DA uses a core database of 434 chemicals with study results from 871 HPPTs, 535 LLNAs, 653 DPRAs, 361 kDPRAs, 1,030 KeratinoSens™, 483 h-CLATs and 388 U-SENS™. The number of studies per chemical is distributed heterogeneously, with a minimum of two studies for any single chemical.

Acknowledgments

ED01 for Chemicals in SARA-ICE Database

The SARA-ICE Model can be used to obtain sensitiser potency estimates and GHS classifications from:
- NAM data only (DPRA, kDPRA, h-CLAT, KeratinoSens, U-Sens)
- in vivo data only (HPPT and/or LLNA)
- combinations of both for a weight-of-evidence estimate

SARA-ICE explicitly quantifies the uncertainty in both the continuous metric of sensitiser potency and discrete GHS classification.


Figure 1. Estimates of ED01 for chemicals in SARA-ICE database. Blue x – the HPPT induction dose following which no individual was sensitised. Orange x – the HPPT induction dose following which at least one subject was sensitised. ED01 estimates vary in precision. Precision in estimates a function of data availability. Standard deviation of estimates ranges from 0.3 – 1.8 units on the log10 scale

Figure 2. Red: Estimate of the average sensitisation rate to cinnamic alcohol given HPPT data only. Bands indicate uncertainty in estimates after accounting for inter and intra study variability (median, 50% and 95% intervals). Blue: ED01 estimates - dermally applied dose resulting in a 1% sensitisation rate (median, 50% and 95% intervals). 'x' shows probability of sensitisation given ED01 estimates from a single HPPT study.

GHS Classification Probabilities

Continuous probability distribution of ED01 approximated into discrete probability distribution for GHS subcategories 1A, 1B and NC.
- Uses threshold of 500 µg/cm² for 1A/1B boundary (UN 2021).
- Uses threshold of 60,000 µg/cm² for 1B/NC boundary (maximum dermal dose in a standard HPPT).
- Probability mass of each GHS subcategory equal to area under curve between thresholds of ED01 distribution.

Figure 3. (a) Example estimate of ED01 distribution with overlay of GHS subcategories 1A, 1B and NC defined thresholds, (b) probability of each GHS subcategory from ED01 distribution.

Distribution across GHS classes does not by itself result in a GHS classification. A decision model needs to be defined in order to obtain distinct SARA-ICE classifications. The proposed decision model requires two confidence thresholds to be defined, one for binary classification, one for subcategory classification conditional on binary class "1" being chosen. For example:

Binary classification threshold, θ_{bin}
Prior probability of binary class 1 is 0.67.
p(NC) for single NAM inputs <0.8
Therefore, set θ_{bin}=0.8

Subcategory classification threshold, θ_{sub}
Prior probability of 1A and 1B, given binary class 1, is 0.50.
Therefore, set θ_{sub} =0.55

Figure 4. OECD LLNA (left) and human (right) benchmark binary classifications (OECD 2021) based upon θ_{bin}=0.8. Grey – inconclusive classification. Orange – sensitiser (GHS 1A/1B). Blue – non-sensitiser (GHS NC). Orange x's to the right of the grey are incorrect classifications, blue x's to the left of the grey are incorrect classifications.

Methylisothiazolinone (MIT) Input Data

The skin sensitisation potential of MIT was evaluated using both NAM data (in chemico DPRA and kDPRA, in vitro KeratinoSens, h-CLAT, and U-Sens) and in vivo data (LLNA and HRIPT).

NAMs
- 1 DPRA study with 97.9% depletion of the cysteine peptide and 0% depletion of lysine peptide (Hoffmann et al. 2022).
- 1 kDPRA study with a log Kmax of -0.25 M-1s-1 (Natsch & Gerberick 2022).
- 1 KeratinoSens™ study with an EC1.5 of 11.78 µM and an IC50 of 138.98 µM (Hoffmann et al. 2022).
- 1 h-CLAT study with a CD86 EC150 of 9.23 µg ml-1, a CD54 EC200 of 7.89 µg ml-1 and an IC50 of 24.7 µg ml-1 (Hoffmann et al. 2022).
- 1 U-Sens™ study with a CD86 EC150 of 9 µg ml-1 (Hoffmann et al. 2022).

In vivo
- 3 LLNA EC3s at 0.4%, 1.9% and 2.2% (Hoffmann et al. 2022).
- 6 HRIPTs with the following results:

Table 1. SARA-ICE Input HRIPT Data for MIT (Giménez-Arnau, A. M. 2016)

Induction dose (µg cm⁻²)	Number tested	Number sensitised
5	97	0
10	100	0
15	98	0
20	116	1
25	210	1
30	75	0

Methylisothiazolinone (MIT) Results

Figure 5. Distribution of ED01 for MIT given;

Blue – NAM data only

Orange – in vivo data only

Green – NAM + in vivo data (WoE)

Figure 6. Probability of each GHS subcategory from ED01 distribution given:

Blue – NAM data only

Orange – in vivo data only

Green – NAM + in vivo data (WoE)

Table 2. SARA-ICE estimated ED01 and GHS sub-category call with probabilities of each class, dependent on input data of either NAM data only, in vivo data only or NAM and in vivo data.

	ED01 percentiles (µg cm⁻²)					GHS categories			
	2.5th	25th	50th	75th	97.5th	Subcategory call	Prob. 1A	Prob. 1B	Prob. NC
NAM	0.75	9.7	37	140	2,400	1A	0.90	0.10	~0
In vivo	32	130	280	670	4,300	1A	0.68	0.32	~0
NAM + in vivo	33	100	180	330	1,200	1A	0.87	0.13	~0

Discussion

The SARA-ICE Model is a probabilistic method that is able to integrate multiple skin sensitisation data inputs in various combinations and will support GHS classification of skin sensitisers, in addition to providing a human-relevant point of departure, with quantified uncertainty, for quantitative risk assessment. Currently, SARA-ICE is undergoing evaluation via the OECD Defined Approach Skin Sensitisation (DASS) Expert Group for potential inclusion in Guideline 497: Defined Approaches on Skin Sensitisation. Ultimately, the SARA-ICE Model will be publicly available in the NICEATM Integrated Chemical Environment (https://ice.ntp.niehs.nih.gov/).

Binary classification performance of the SARA-ICE Model using NAM inputs only against LLNA and human benchmarks results in an inconclusive rate of around 33% for benchmark Class 1 and 40% for the NC benchmark. Sensitivity, specificity and balanced accuracy for conclusive predictions was 95%, 89% and 92%, respectively versus LLNA benchmarks, and sensitivity, specificity and balanced accuracy for conclusive predictions was 94%, 100% and 97%, respectively for human benchmarks.

The SARA-ICE Model estimates with high probability that MIT is a sensitiser and most likely to be in the 1A category, with the most confident prediction of 1A resulting from use of NAM data only (0.90). The Scientific Committee on Consumer Safety (SCCS), identified a NESIL of 15µg/cm². In comparison, the SARA-ICE Model estimates a median ED01 of between 37-260µg/cm² for estimates based upon NAM data and in vivo data, respectively. The 2.5th of the ED01 was estimated as between 0.75-33µg/cm² based upon NAM data and NAM + in vivo data, respectively. These estimates are comparable to the DSA metric of 210µg/cm² transformed from the ANN D_hC_KS estimated EC3 of 0.83%.

References

Giménez-Arnau 2016. Opinion of the Scientific Committee on Consumer safety (SCCS)–opinion on the safety of the use of methylisothiazolinone (MI)(P94), in cosmetic products (sensitisation only). Regulatory Toxicology and Pharmacology, 76, 211-212. https://www.sciencedirect.com/science/article/pii/S0273230016300010

Hoffmann et al. 2022. Expansion of the Cosmetics Europe skin sensitisation database with new substances and PPRA data. Regulatory Toxicology and Pharmacology, 131, 105169. https://www.sciencedirect.com/science/article/pii/S0273230022000563.

Natsch & Gerberick 2022. Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment. ALTEX-Alternatives to animal experimentation, 39(4), 636-646. https://www.altex.org/index.php/altex/article/view/2421

OECD 2021. Supporting Document to the OECD Guideline 497 on Defined Approaches for Skin Sensitisation. https://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/CBC/MONO(2021)11&docLanguage=En

Reynolds et al. 2019. Probabilistic prediction of human skin sensitiser potency for use in next generation risk assessment. Computational Toxicology, 9, 36-49. https://www.sciencedirect.com/science/article/pii/S2468111318300872

Reynolds et al. 2022. Decision making in next generation risk assessment for skin allergy: Using historical clinical experience to benchmark risk. Regulatory Toxicology and Pharmacology, 134, 105219. https://www.sciencedirect.com/science/article/pii/S0273230022001064

Strickland et al. 2022. Application of Defined Approaches to Assess Skin Sensitization Potency of Isothiazolinone Compounds. Applied In Vitro Toxicology, 8(4), 117-128. https://www.liebertpub.com/doi/abs/10.1089/aivt.2022.0014

UN 2021. Globally Harmonised System of Classification and Labelling of Chemicals (GHS). https://unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs_rev04/English/ST-SG-AC10-30-Rev4e.pdf

NICEATM Presentations at SOT 2023

Unilever Presentations at SOT 2023